The present invention pertains to medical devices and methods for making and using medical devices. More particularly, the present invention pertains to cannulation devices for ERCP.
A wide variety of intracorporeal medical devices have been developed for medical use, for example, intravascular use. These devices are manufactured by any one of a variety of different manufacturing methods and may be used according to any one of a variety of methods. Of the known intracorporeal medical devices and methods for making and using the same, each has certain advantages and disadvantages. There is an ongoing need to provide alternative intracorporeal medical devices as well as alternative methods for making and using intracorporeal medical devices.
The invention provides design, material, manufacturing method, and use alternatives for intracorporeal medical devices. An example may be found in a cannulation device that is adapted to be advanced through an endoscope to a position proximate a patient's duodenum in order to gain access to the patient's common bile duct. The cannulation device includes an elongate shaft extending to an atraumatic distal tip, a first guidewire lumen extending through the elongate shaft, the first guidewire lumen terminating at a first oblique guidewire port, and a second guidewire lumen extending through the elongate shaft, the second guidewire lumen terminating at a second oblique guidewire port.
Alternatively or additionally, the first oblique guidewire port may be adapted to guide a guidewire extending through the first guidewire lumen in a first direction relative to the atraumatic tip.
Alternatively or additionally, the second oblique guidewire port may be adapted to guide a guidewire extending through the second guidewire lumen in a second direction, different from the first direction, relative to the atraumatic tip.
Alternatively or additionally, the atraumatic distal tip may include a tapered outer surface, with the first oblique guidewire port disposed on a first portion of the tapered outer surface and the second oblique guidewire port disposed on a second portion of the tapered outer surface circumferentially spaced from the first portion of the tapered outer surface.
Alternatively or additionally, the first guidewire lumen may be parallel with the second guidewire lumen within a proximal portion of the cannulation device.
Alternatively or additionally, the first guidewire lumen may diverge radially from the second guidewire lumen within a distal portion of the cannulation device.
Alternatively or additionally, the cannulation device may further include a cutting wire extending through the elongate shaft.
Alternatively or additionally, the cannulation device may be adapted to be advanced through an endoscope.
Alternatively or additionally, the cannulation device may be adapted for accessing the patient's common bile duct from a position proximate the patient's ampulla of vater.
Another example may be found in a cannulation device that is adapted to be advanced through an endoscope to a position proximate a patient's duodenum in order to gain access to the patient's common bile duct. The cannulation device includes an elongate shaft extending to an atraumatic distal tip and a guidewire lumen extending through the elongate shaft, the guidewire lumen terminating at a guidewire port disposed within the atraumatic distal tip. An inflatable balloon is disposed relative to the atraumatic distal tip, the inflatable balloon inflatable from a collapsed configuration to an expanded configuration in which the inflatable balloon is adapted to occlude the patient's pancreatic duct. An inflation lumen extends through the elongate shaft and is fluidly coupled with the inflatable balloon.
Alternatively or additionally, the inflatable balloon may be further adapted to, when inflated, push the atraumatic distal tip away from the patient's pancreatic duct and towards the patient's common bile duct, thereby helping to align the guidewire port with the common bile duct.
Alternatively or additionally, the inflatable balloon may be disposed along a side of the atraumatic distal tip.
Alternatively or additionally, the inflatable balloon, when in its collapsed configuration, may form part of the atraumatic distal tip.
Alternatively or additionally, the cannulation device may be adapted for accessing the patient's common bile duct from a position proximate the patient's ampulla of vater.
Another example may be found in a cannulation device that is adapted to be advanced through an endoscope to a position proximate a patient's duodenum in order to gain access to the patient's common bile duct. The cannulation device includes an elongate shaft extending to an atraumatic distal tip and a guidewire lumen extending through the elongate shaft, the guidewire lumen terminating at a guidewire port disposed within the atraumatic distal tip. An expandable element is disposed within the guidewire lumen, the expandable element expandable from a collapsed configuration in which the expandable element is disposed within the guidewire lumen and an extended configuration in which a portion of the expandable element extends distally from the guidewire port, the expandable element adapted to permit a guidewire to extend through an interior of the expandable element.
Alternatively or additionally, the expandable element may be adapted to occlude the patient's pancreatic duct.
Alternatively or additionally, the cannulation device may be adapted for accessing the patient's common bile duct from a position proximate the patient's ampulla of vater.
Alternatively or additionally, the expandable element may include an eversion-type soft robot.
Alternatively or additionally, the expandable element may include an inverted polymeric sheath.
Alternatively or additionally, an end of the expandable element may be secured relative to a distal end of the cannulation device.
The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present invention. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.
The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:
While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.
ERCP (Endoscopic Retrograde Cholangiopancreatography) is a procedure that utilizes both endoscopic and fluoroscopic techniques to diagnose and treat issues arising in the Common bile duct and Pancreatic ducts. To view the ducts endoscopically and fluoroscopically, access through the ampulla of vater is required, and proper position of the papilla is a key in increasing cannulation success. There is a desire to limit or even prevent multiple cannulations of the pancreatic duct, as multiple cannulations of the pancreatic duct can lead to pancreatitis. In some cases, anatomical features, inflammation and adenomas of the papilla or periampullary diverticulum can further complicate attempts to successfully cannulate the common bile duct without irritating the pancreatic duct.
An endoscope 22 is shown positioned within the duodenum 12. A guidewire 24 is shown exiting the endoscope 22, passing through the ampulla of vater 18 and into the CBD 14.
In some cases, the first oblique guidewire port 36 and the second oblique guidewire port 40 are both disposed within the atraumatic distal tip 42. The atraumatic distal tip 42 may be considered as having a tapered outer surface 44, with the first oblique guidewire port 36 disposed on a first portion of the tapered outer surface 44 and the second oblique guidewire port 40 disposed on a second portion of the tapered outer surface 44 that is circumferentially spaced from the first portion of the tapered outer surface 44. In some cases, at least part of the atraumatic distal tip 42 may be considered as having a frustoconical shape or even a conical shape.
A first guidewire 46 is shown extending through the first guidewire lumen 34 and out the first oblique guidewire port 36 and a second guidewire 48 is shown extending through the second guidewire lumen 38 and out the second oblique guidewire port 40. As can be seen, the first guidewire 46 extends out of the cannulation device 26 in a first direction indicated by an arrow 50 while the second guidewire 48 extends out of the cannulation device 26 in a second direction indicated by an arrow 52. It will be appreciated that depending on the particular orientation of the cannulation device 26 within the duodenum 12, one of the first oblique guidewire port 36 and the second oblique guidewire port 40 may be more closely aligned with the CBD 14 while the other of the first oblique guidewire port 36 and the second oblique guidewire port 40 may be more closely aligned with the PD 16.
In use, a physician or other professional will advance a guidewire through one of the guidewire lumens 34 and 38. As an example, let's assume that the physician or other professional advances the first guidewire 46 through the first guidewire lumen 34 and out the first oblique guidewire port 36. While viewing under fluoroscopy, the physician or other professional will be able to see whether the first guidewire 46 has cannulated the CBD 14 or the PD 16. If they see that the first guidewire 46 has successfully cannulated the CBD 14, the second guidewire 48 will not be used, and the physician or other professional can then continue with the ERCP procedure.
However, if the physician or other professional determines that the first guidewire 46 has cannulated the PD 16, they will leave the first guidewire 46 in place for the time being while they advance the second guidewire 48 through the second guidewire lumen 38 and out the second oblique guidewire port 40. Because the first guidewire 46 is positioned within the PD 16, that means that the second oblique guidewire port 40 may be more closely aligned with the CBD 14. Moreover, having the first guidewire 46 positioned within the PD 16 means that it would be much more difficult to accidently advance the second guidewire 48 into the PD 16 while the first guidewire 46 is already there. Accordingly, advancing the second guidewire 48 through the second guidewire lumen 38 and out the second oblique guidewire port 40 should allow successful cannulation of the CBD 14. Once the CBD 14 has been successfully cannulated, the first guidewire 48 may be withdrawn proximally from the PD 16 and the physician or other professional can then continue with the ERCP procedure. In some cases, the cannulation device 26 may be formed of any of a variety of polymers, such as but not limited to nylon, HDPE (high density polyethylene), PEBAX, Arnitel, Vestamid, Grilamid or a combination of polymers. In some cases, the cannulation device 26 may be a cutting or cauterization wire 54. Wire components may include SS316LVM, Nitinol, platinum or titanium, for example.
In some cases, instead of being configured to accommodate two guidewires extending through two distinct guidewire lumens, a cannulation device may instead employ an inflatable balloon to increase the likelihood that a single guidewire advanced through the cannulation device will successfully cannulate the CBD 14 rather than the PD 16.
In use, a physician or other professional will move the cannulation device 82 into position, and will advance the guidewire 90 through the guidewire lumen 88. While viewing under fluoroscopy, the physician or other professional will be able to see whether the guidewire 90 has cannulated the CBD 14 or the PD 16. If they see that the guidewire 90 has successfully cannulated the CBD 14, the physician or other professional can then continue with the ERCP procedure.
However, if the physician or other professional determines that they have instead cannulated the PD 16, they will withdraw the guidewire 90 and will inflate the inflatable balloon 82. Because the inflatable balloon 82 (when inflated) blocks access to the PD 16, the physician or other professional can once again advance the guidewire 90, which will successfully cannulate the CBD 14. In some cases, the physician or other professional may instead begin the procedure by inflating the inflatable balloon 92 in order to block access to the PD 16 and thus protect the PD 16 against cannulation. In some cases, the cannulation device 82 may be formed of any of a variety of polymers, such as but not limited to nylon, polyurethane, HDPE (high density polyethylene), PEBAX, Arnitel, Vestamid, Grilamid or a combination of polymers. The inflatable balloon 82 may be formed of any medical grade elastomer, such as but not limited to silicone or a thermoplastic elastomer.
In some cases, a cannulation device may use an expandable element such as but not limited to an eversion-type soft robot in order to increase the likelihood that a single guidewire advanced through the cannulation device will successfully cannulate the CBD 14 rather than the PD 16.
In some cases, the expandable element 118 may be secured relative to the lumen 116 at a point 120. The expandable element 118 may be movable between a collapsed configuration, as seen for example in
However, if the physician or other professional determines that they have instead cannulated the PD 16, they will withdraw the guidewire 138 and will cause the expandable element 136 to expand into its extended configuration in which the expandable element 136 extends into the CBD 14 (as shown in
The materials that can be used for the various components of the cannulation devices may include those commonly associated with medical devices. Various components of the cannulation devices described herein may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, combinations thereof, and the like, or any other suitable material. Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; combinations thereof; and the like; or any other suitable material.
As alluded to above, within the family of commercially available nickel-titanium or nitinol alloys, is a category designated “linear elastic” or “non-super-elastic” which, although may be similar in chemistry to conventional shape memory and super elastic varieties, may exhibit distinct and useful mechanical properties. Linear elastic and/or non-super-elastic nitinol may be distinguished from super elastic nitinol in that the linear elastic and/or non-super-elastic nitinol does not display a substantial “superelastic plateau” or “flag region” in its stress/strain curve like super elastic nitinol does. Instead, in the linear elastic and/or non-super-elastic nitinol, as recoverable strain increases, the stress continues to increase in a substantially linear, or a somewhat, but not necessarily entirely linear relationship until plastic deformation begins or at least in a relationship that is more linear that the super elastic plateau and/or flag region that may be seen with super elastic nitinol. Thus, for the purposes of this disclosure linear elastic and/or non-super-elastic nitinol may also be termed “substantially” linear elastic and/or non-super-elastic nitinol.
In some cases, linear elastic and/or non-super-elastic nitinol may also be distinguishable from super elastic nitinol in that linear elastic and/or non-super-elastic nitinol may accept up to about 2-5% strain while remaining substantially elastic (e.g., before plastically deforming) whereas super elastic nitinol may accept up to about 8% strain before plastically deforming. Both of these materials can be distinguished from other linear elastic materials such as stainless steel (that can also can be distinguished based on its composition), which may accept only about 0.2-0.44% strain before plastically deforming.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy is an alloy that does not show any martensite/austenite phase changes that are detectable by DSC and DMTA analysis over a large temperature range. For example, in some embodiments, there may be no martensite/austenite phase changes detectable by DSC and DMTA analysis in the range of about −60° C. to about 120° C. in the linear elastic and/or non-super-elastic nickel-titanium alloy. The mechanical bending properties of such material may therefore be generally inert to the effect of temperature over this very broad range of temperature. In some embodiments, the mechanical bending properties of the linear elastic and/or non-super-elastic nickel-titanium alloy at ambient or room temperature are substantially the same as the mechanical properties at body temperature, for example, in that they do not display a super-elastic plateau and/or flag region. In other words, across a broad temperature range, the linear elastic and/or non-super-elastic nickel-titanium alloy maintains its linear elastic and/or non-super-elastic characteristics and/or properties and has essentially no yield point.
In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Some examples of nickel titanium alloys are disclosed in U.S. Pat. Nos. 5,238,004 and 6,508,803, which are incorporated herein by reference. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.
In at least some embodiments, various components of the cannulation devices described herein include a radiopaque material including those listed herein or other suitable radiopaque materials.
In some embodiments, a degree of MRI compatibility is imparted into the cannulation devices described herein. For example, to enhance compatibility with Magnetic Resonance Imaging (MRI) machines, it may be desirable to make various components of the cannulation devices described herein, in a manner that would impart a degree of MRI compatibility. For example, various components of the cannulation devices described herein, or portions thereof, may be made of a material that does not substantially distort the image and create substantial artifacts (artifacts are gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. Various components of the cannulation devices described herein, or portions thereof, may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.
Some examples of suitable polymers that may be used to form various components of the cannulation devices described herein may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, ionomers, biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6% LCP.
In some embodiments, the exterior surface of the cannulation devices described herein may include a coating, for example a lubricious, a hydrophilic, a protective, or other type of coating. Hydrophobic coatings such as fluoropolymers provide a dry lubricity which improves device handling and exchanges. Lubricious coatings improve steerability and improve lesion crossing capability. Suitable lubricious polymers may include silicone and the like, polymers such as high-density polyethylene (HDPE), polytetrafluoroethylene (PTFE), polyarylene oxides, polyvinylpyrolidones, polyvinylalcohols, hydroxy alkyl cellulosics, algins, saccharides, caprolactones, and the like, and mixtures and combinations thereof. Hydrophilic polymers may be blended among themselves or with formulated amounts of water insoluble compounds (including some polymers) to yield coatings with suitable lubricity, bonding, and solubility. Some other examples of such coatings and materials and methods used to create such coatings can be found in U.S. Pat. Nos. 6,139,510 and 5,772,609, the entire disclosures of which are incorporated herein by reference.
It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.
This application claims the benefit of priority under 35 U.S.C. § 119 of U.S. Provisional Application No. 63/400,366, filed Aug. 23, 2022, the entire disclosure of which is hereby incorporated by reference.
Number | Date | Country | |
---|---|---|---|
63400366 | Aug 2022 | US |